Market Research Logo

Herpes Zoster (Shingles) - Pipeline Review, H2 2018

Herpes Zoster (Shingles) - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H2 2018, provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape.

Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Herpes Zoster (Shingles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 7, 1 and 2 respectively.

Herpes Zoster (Shingles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Herpes Zoster (Shingles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Herpes Zoster (Shingles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Herpes Zoster (Shingles) - Overview
Herpes Zoster (Shingles) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Herpes Zoster (Shingles) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
CPL Biologicals Pvt Ltd
GC Pharma
GeneOne Life Science Inc
GlaxoSmithKline Plc
NAL Pharmaceuticals Ltd
NanoViricides Inc
Vaccitech Ltd
XBiotech Inc
Herpes Zoster (Shingles) - Drug Profiles
B-1006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRV-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSB-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLS-5100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Shingles - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAL-3220 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Shingles - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
varicella zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Herpes Zoster (Shingles) - Dormant Projects
Herpes Zoster (Shingles) - Discontinued Products
Herpes Zoster (Shingles) - Product Development Milestones
Featured News & Press Releases
Aug 07, 2018: Nanoviricides reports its topical dermal Shingles candidates effective in reducing pain in animal study
Jun 29, 2018: Klobuchar Urges Pharmaceutical Company to Take Action to Alleviate Shortage of Its Shingles Vaccine
Jun 26, 2018: Progress of NanoViricides' Shingles Drug Program Presented at the 31st International Conference on Antiviral Research
Jun 18, 2018: National Advisory Committee on Immunization (NACI) recommends SHINGRIX for the prevention of shingles for adults aged 50 and up
Jun 04, 2018: New Shingles Vaccine Aims to Protect More People
Apr 23, 2018: Quebecs Committee on Immunization recommends preferential use of SHINGRIX for the prevention of shingles in adults aged 50 and up
Apr 09, 2018: NanoViricides Reports Good Safety Profile of Topical Dermal Drug Candidates; Dr. Diwan, President, Will Present at the MicroCap Conference in New York City
Mar 23, 2018: Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over
Mar 16, 2018: CVS Pharmacy Now Offering New Shingles Vaccine at Locations Nationwide
Mar 08, 2018: Most Walgreens and Duane Reade Pharmacies Nationwide Now Offering New Shingles Vaccine, Shingrix
Jan 26, 2018: GSK’s Shingrix receives positive opinion from the CHMP in Europe for the prevention of shingles in adults aged 50 and over
Dec 06, 2017: Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates
Dec 06, 2017: New data supports the safety and efficacy of GSK’s Shingrix in preventing shingles in autologous hematopoietic stem cell transplant patients
Nov 20, 2017: New Shingles Vaccine: CUMC Experts Discuss what it Means for Patients
Oct 26, 2017: Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Center
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Herpes Zoster (Shingles), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Herpes Zoster (Shingles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2018
Herpes Zoster (Shingles) - Pipeline by CPL Biologicals Pvt Ltd, H2 2018
Herpes Zoster (Shingles) - Pipeline by GC Pharma, H2 2018
Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science Inc, H2 2018
Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H2 2018
Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd, H2 2018
Herpes Zoster (Shingles) - Pipeline by NanoViricides Inc, H2 2018
Herpes Zoster (Shingles) - Pipeline by Vaccitech Ltd, H2 2018
Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, H2 2018
Herpes Zoster (Shingles) - Dormant Projects, H2 2018
Herpes Zoster (Shingles) - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Herpes Zoster (Shingles), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report